JPWO2021119810A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2021119810A5
JPWO2021119810A5 JP2022537400A JP2022537400A JPWO2021119810A5 JP WO2021119810 A5 JPWO2021119810 A5 JP WO2021119810A5 JP 2022537400 A JP2022537400 A JP 2022537400A JP 2022537400 A JP2022537400 A JP 2022537400A JP WO2021119810 A5 JPWO2021119810 A5 JP WO2021119810A5
Authority
JP
Japan
Prior art keywords
delivery system
oral delivery
protein
powder
polysaccharide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022537400A
Other languages
Japanese (ja)
Other versions
JP2023506539A (en
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2020/051726 external-priority patent/WO2021119810A1/en
Publication of JP2023506539A publication Critical patent/JP2023506539A/en
Publication of JPWO2021119810A5 publication Critical patent/JPWO2021119810A5/ja
Pending legal-status Critical Current

Links

Claims (18)

タンパク質粉末および多糖粉末混合物を含む乾燥均一混合物と、その中に分散された有効成分とを含むか、またはそれらから本質的になる経口送達系であって、前記経口送達系を胃液に浸漬すると、前記タンパク質粉末および多糖粉末混合物が、イン・サイチュ(in situ)でタンパク質／多糖複合コアセルベートを形成し、それによって胃保護および／または前記有効成分に放出調節をもたらし、前記経口送達系におけるタンパク質粉末と多糖粉末の比率を変更すると、胃保護のレベルおよび／または前記有効成分の放出速度が変化し、
前記多糖粉末が、以下の粉末流動特性のうちの１つ以上を有するか、または有するように調整される、経口送達系：
（ａ）約２８、２９、３０、３１、３２、３３、３４、３５、３６、３７、３８、３９、４０、４１、４２、４３、４４、４５、４６、４７、４８、４９、４９、５０、５１、５２、５３、５４、５５、５６、５７、５８、５９、６０、６１、６２、６３、６４、または６５度より大きい安息角（α）；
（ｂ）約１０、１１、１２、１３、１４、１５、１６、１７、１８、１９、２０、２１、２２、２３、２４、２５、２６、２７、２８、２９、３０、３１、３２、３３、３４、３５、３６、３７、３８、３９、４０、４１、４２、４３、４４、４５、４６、４７、４８、４９、または５０を超える動的凝集指数；
（ｃ）約１５、１６、１７、１８、１９、２０、２１、２２、２３、２４、２５、２６、２７、２８、２９、３０、３１、３２、３３、３４、３５、３６、３７、または３８％より大きい圧縮度（Ｃａｒｒ指数）；
（ｄ）約１．１８、１．１９、１．２、１．２１、１．２２、１．２３、１．２４、１．２５、１．２６、１．２７、１．２８、１．２９、１．３、１．３１、１．３２、１．３３、１．３４、１．３５、１．３６、１．３７、１．３８、１．３９、１．４、１．４１、１．４２、１．４３、１．４４、１．４５、１．４６、１．４７、１．４８、１．４９、１．５、１．５１、１．５２、１．５３、１．５４、１．５５、１．５６、１．５７、１．５８、１．５９または１．６より大きいＨａｕｓｎｅｒ比；または
（ｅ）（ａ）～（ｄ）の任意の組み合わせ。 An oral delivery system comprising, or consisting essentially of, a dry homogeneous mixture comprising a protein powder and a polysaccharide powder mixture and an active ingredient dispersed therein, the oral delivery system comprising: immersing said oral delivery system in gastric fluid; The protein powder and polysaccharide powder mixture forms a protein/polysaccharide complex coacervate in situ, thereby providing gastroprotection and/or modified release to the active ingredient, and the protein powder and polysaccharide powder mixture in the oral delivery system. Changing the proportion of polysaccharide powder changes the level of gastroprotection and/or the rate of release of said active ingredient;
Oral delivery system , wherein the polysaccharide powder has or is tailored to have one or more of the following powder flow properties :
(a) about 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 49, An angle of repose (α) greater than 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, or 65 degrees;
(b) about 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, a dynamic aggregation index greater than 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50;
(c) about 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, or compression degree (Carr index) greater than 38%;
(d) about 1.18, 1.19, 1.2, 1.21, 1.22, 1.23, 1.24, 1.25, 1.26, 1.27, 1.28, 1. 29, 1.3, 1.31, 1.32, 1.33, 1.34, 1.35, 1.36, 1.37, 1.38, 1.39, 1.4, 1.41, 1.42, 1.43, 1.44, 1.45, 1.46, 1.47, 1.48, 1.49, 1.5, 1.51, 1.52, 1.53, 1. Hausner ratio greater than 54, 1.55, 1.56, 1.57, 1.58, 1.59 or 1.6; or
(e) Any combination of (a) to (d) . 前記多糖粉末が、（ａ）、（ｂ）、（ｃ）および（ｄ）で定義されるすべての粉末流動特性を有するか、または有するように調整される、請求項１に記載の経口送達系。 2. The oral delivery system of claim 1 , wherein the polysaccharide powder has or is tailored to have all powder flow properties defined in (a), (b), (c) and (d). . 前記多糖のｐＫａ未満のｐＨの溶液に経口送達系を浸漬すると、前記タンパク質粉末および多糖粉末混合物が、イン・サイチュでタンパク質／多糖複合コアセルベートを形成する、請求項１または２に記載の経口送達系。 3. The oral delivery system of claim 1 or 2 , wherein the protein powder and polysaccharide powder mixture forms a protein/polysaccharide complex coacervate in situ when the oral delivery system is immersed in a solution with a pH below the pKa of the polysaccharide. . （ａ）前記経口送達系において前記タンパク質粉末（ｐｒｏｔｅｉｎ ｐｏｗｅｒ）に対する前記多糖粉末の比率を高めると、胃保護のレベルが高まる、および／または前記有効成分の放出速度が低下する；
（ｂ）前記経口送達系における多糖粉末対タンパク質粉末（ｐｒｏｔｅｉｎ ｐｏｗｅｒ）の重量比が、１：２０～１：１、１：１５～１：１．５、１：１０～１：２、１：９．５～１：２．５、１：９～１：３、または１：８．５～１：３．５、１：８～１：４、１：７．５～１：４．５、または１：７～１：５である；
（ｃ）前記経口送達系が、約５％～５０％、１０％～４５％、１５％～４０％、または２０％～３５重量／重量％の前記タンパク質粉末と前記多糖粉末の混合物を含む、または
（ｄ）それらの任意の組み合わせである、
請求項１～３のいずれか一項に記載の経口送達系。 (a) increasing the ratio of the polysaccharide powder to the protein power in the oral delivery system increases the level of gastroprotection and/or reduces the rate of release of the active ingredient;
(b) The weight ratio of polysaccharide powder to protein power in the oral delivery system is 1:20 to 1:1, 1:15 to 1:1.5, 1:10 to 1:2, 1: 9.5-1:2.5, 1:9-1:3, or 1:8.5-1:3.5, 1:8-1:4, 1:7.5-1:4.5 , or 1:7 to 1:5;
(c) said oral delivery system comprises about 5% to 50%, 10% to 45%, 15% to 40%, or 20% to 35% w/w of a mixture of said protein powder and said polysaccharide powder ; or (d) any combination thereof;
Oral delivery system according to any one of claims 1 to 3 . （ａ）前記タンパク質粉末および多糖粉末混合物が、２ｇ／ＬのＮａＣｌおよび０．１ｇ／Ｌのペプシンを含むｐＨ１．０で３７体積／体積％の希釈ＨＣｌ溶液からなる模擬胃液（ＳＧＦ）に前記経口送達系を浸漬すると、イン・サイチュで前記タンパク質／多糖複合コアセルベートを形成する；
（ｂ）前記有効成分の放出速度が、前記経口送達系を胃液に浸漬すると、イン・サイチュで形成される前記タンパク質／多糖複合コアセルベートの強度に反比例する；
（ｃ）前記経口送達系をＳＧＦに浸漬した際にイン・サイチュで形成される前記タンパク質／多糖複合コアセルベートが、分子内ベータ－シート構造、アルファ－ヘリックス構造、および／または不規則構造の存在を特徴とする（例えば、フーリエ変換赤外（ＦＴＩＲ）分光法によって測定される場合）；または
（ｄ）それらの任意の組み合わせである、
請求項１～４のいずれか一項に記載の経口送達系。 (a) The protein powder and polysaccharide powder mixture is orally added to simulated gastric fluid (SGF) consisting of a 37% v/v diluted HCl solution at pH 1.0 containing 2 g/L NaCl and 0.1 g/L pepsin. immersing the delivery system forms the protein /polysaccharide complex coacervate in situ;
(b) the rate of release of said active ingredient is inversely proportional to the strength of said protein/polysaccharide complex coacervate formed in situ upon immersion of said oral delivery system in gastric fluid;
(c) the protein/polysaccharide complex coacervates formed in situ upon immersion of the oral delivery system in SGF exhibit the presence of intramolecular beta-sheet, alpha-helical, and/or disordered structures; (e.g., as measured by Fourier Transform Infrared (FTIR) spectroscopy); or (d) any combination thereof;
Oral delivery system according to any one of claims 1 to 4 . （ｉ）遅延放出経口送達系；
（ｉｉ）持続放出経口送達系；
（ｉｉｉ）非製剤化有効成分の投与と比較して、経口投与時に前記有効成分に対して胃保護を強化した経口送達系；または
（ｉｖ）それらの任意の組み合わせ
である、請求項１～５のいずれか一項に記載の経口送達系。 (i) a delayed release oral delivery system;
(ii) sustained release oral delivery system;
(iii) an oral delivery system that provides enhanced gastroprotection for the active ingredient upon oral administration compared to administration of unformulated active ingredients; or (iv) any combination thereof Oral delivery system according to any one of . 経口送達系を、ＳＧＦに３７℃で２時間浸漬し、続いて模擬腸液（ＳＩＦ）に浸漬することを含み、前記ＳＧＦが、２ｇ／ＬのＮａＣｌおよび０．１ｇ／Ｌのペプシンを含有する３７体積／体積％の希釈ＨＣｌ溶液、ｐＨ１．０からなり、前記ＳＩＦが、０．５ｇ／Ｌのパンクレアチンを含有するｐＨ６．９の５０ｍＭ ＮａＨ２ＰＯ４またはＫＨ２ＰＯ４緩衝液からなる、溶出試験時に、
（ｉ）遅延放出経口送達系が、多糖粉末を含まない対応する経口送達系と比較して、前記有効成分の５０％が放出されるのに必要な時間を少なくとも３０、６０、９０，１２０，１５０，１８０，２１０、または２４０分遅延させる；
（ｉｉ）持続放出経口送達系が、少なくとも３、４、５、６、７、８、９、１０、１１、１２、１３、１４、１５、１６、１７、または１８時間にわたって前記有効成分の放出をもたらす；および／または
（ｉｉ）前記経口送達系が、非製剤化有効成分の投与と比較して、前記有効成分に対して胃保護を強化する；
請求項６に記載の経口送達系。 The oral delivery system was immersed in SGF for 2 hours at 37°C, followed by immersion in simulated intestinal fluid (SIF), where the SGF contained 2 g/L NaCl and 0.1 g/L pepsin. Elution consisting of a dilute HCl solution, pH 1.0, at % vol/vol, the SIF consisting of 50 mM NaH 2 PO 4 or KH 2 PO 4 buffer, pH 6.9, containing 0.5 g/L pancreatin. During the exam,
(i) the delayed release oral delivery system requires at least 30, 60, 90, 120, delay by 150, 180, 210, or 240 minutes;
(ii) the sustained release oral delivery system releases said active ingredient over a period of at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, or 18 hours; and/or (ii) said oral delivery system provides enhanced gastroprotection for said active ingredient compared to administration of an unformulated active ingredient;
7. Oral delivery system according to claim 6 . 前記タンパク質粉末は、天然タンパク質；食品グレードおよび／または医薬品グレードのタンパク質；天然タンパク質；変性タンパク質；化学修飾されていないタンパク質；化学修飾タンパク質；植物タンパク質；動物タンパク質；乳タンパク質；マメ科植物タンパク質；果実タンパク質；穀物タンパク質；またはそれらの任意の混合物を含むか、またはそれらからなる、請求項１～７のいずれか一項に記載の経口送達系。 The protein powder may include natural protein; food grade and/or pharmaceutical grade protein; natural protein; denatured protein; non-chemically modified protein ; chemically modified protein ; plant protein ; animal protein; milk protein; Oral delivery system according to any one of claims 1 to 7, comprising or consisting of a plant protein ; a fruit protein; a cereal protein; or any mixture thereof. 前記多糖粉末が、天然多糖；食品グレードおよび／または医薬品グレードの多糖；化学修飾されていない多糖；化学修飾多糖；植物多糖；動物多糖；負電荷／酸性基を含む多糖（アニオン性多糖）；カラゲナン（例えば、カッパ－カラゲナン）；キサンタンガム；アルギナート；ペクチン粉末；寒天、ジェラン、グアーガム、カルボキシメチルセルロース、ローカストビーンガム、マンナン、グルコマンナン、ヒアルロナン、タマリンドガム、オオバコ種子ガム、タラガム、アカシアガム、アラビアガム、ガティガム、トラガカントガム、カラヤガム、カッシアガム、ラムサンガム、ウェランガム、マクロホモプシスガム、カードラン、プルラン、フコイダン、またはそれらの任意の混合物を含むか、またはそれらからなる、請求項１～８のいずれか一項に記載の経口送達系。 The polysaccharide powder contains natural polysaccharides; food grade and/or pharmaceutical grade polysaccharides; non-chemically modified polysaccharides; chemically modified polysaccharides; plant polysaccharides; animal polysaccharides; polysaccharides containing negative charges/acidic groups (anionic polysaccharides); carrageenan. (e.g. kappa-carrageenan); According to any one of claims 1 to 8 , comprising or consisting of gum gati, gum tragacanth, gum karaya, gum cassia, ramsan gum, welan gum, gum macrohomopsis, curdlan, pullulan, fucoidan, or any mixture thereof. oral delivery system. 前記有効成分が、栄養補助食品、薬物、プロバイオティクス、ビタミン、アミノ酸、食品抽出物またはハーブ系サプリメントである、請求項１～９のいずれか一項に記載の経口送達系。 Oral delivery system according to any one of claims 1 to 9 , wherein the active ingredient is a nutraceutical, drug, probiotic, vitamin, amino acid, food extract or herbal supplement. １種以上の栄養補助的または薬学的に許容される賦形剤および／または添加剤をさらに含む、請求項１～１０のいずれか一項に記載の経口送達系。 Oral delivery system according to any one of claims 1 to 10 , further comprising one or more nutraceutical or pharmaceutically acceptable excipients and/or additives . 前記添加剤が、微結晶セルロース、ステアリン酸マグネシウム、および／または二酸化ケイ素であるか、それらを含む、請求項１１に記載の経口送達系。 12. The oral delivery system of claim 11 , wherein the additive is or comprises microcrystalline cellulose, magnesium stearate, and/or silicon dioxide. 錠剤またはカプセル剤である、請求項１～１２のいずれか一項に記載の経口送達系。 Oral delivery system according to any one of claims 1 to 12 , which is a tablet or capsule. 経口送達系が、腸溶性コーティングを含まない、請求項１～１３のいずれか一項に記載の経口送達系。 An oral delivery system according to any one of claims 1 to 13 , wherein the oral delivery system does not include an enteric coating. タンパク質粉末および多糖粉末を含む乾燥均一混合物中に有効成分を分散させることと、得られた混合物を固体経口剤形に製剤化することとを含み、前記固体経口剤形を胃液に浸漬すると、イン・サイチュでタンパク質／多糖複合コアセルベートが形成されるように、前記多糖粉末が、前記タンパク質粉末との相互作用を可能にする粉末流動特性を有し、それにより前記有効成分に胃保護および／または放出調節が付与される、固体経口剤形を調製する方法であって、
前記多糖粉末が、以下の粉末流動特性のうちの１つ以上を有するか、または有するように調整される、方法：
（ａ）約２８、２９、３０、３１、３２、３３、３４、３５、３６、３７、３８、３９、４０、４１、４２、４３、４４、４５、４６、４７、４８、４９、４９、５０、５１、５２、５３、５４、５５、５６、５７、５８、５９、６０、６１、６２、６３、６４、または６５度より大きい安息角（α）；
（ｂ）約１０、１１、１２、１３、１４、１５、１６、１７、１８、１９、２０、２１、２２、２３、２４、２５、２６、２７、２８、２９、３０、３１、３２、３３、３４、３５、３６、３７、３８、３９、４０、４１、４２、４３、４４、４５、４６、４７、４８、４９、または５０を超える動的凝集指数；
（ｃ）約１５、１６、１７、１８、１９、２０、２１、２２、２３、２４、２５、２６、２７、２８、２９、３０、３１、３２、３３、３４、３５、３６、３７、または３８％より大きい圧縮度（Ｃａｒｒ指数）；
（ｄ）約１．１８、１．１９、１．２、１．２１、１．２２、１．２３、１．２４、１．２５、１．２６、１．２７、１．２８、１．２９、１．３、１．３１、１．３２、１．３３、１．３４、１．３５、１．３６、１．３７、１．３８、１．３９、１．４、１．４１、１．４２、１．４３、１．４４、１．４５、１．４６、１．４７、１．４８、１．４９、１．５、１．５１、１．５２、１．５３、１．５４、１．５５、１．５６、１．５７、１．５８、１．５９または１．６より大きいＨａｕｓｎｅｒ比；または
（ｅ）（ａ）～（ｄ）の任意の組み合わせ。 dispersing the active ingredient in a dry homogeneous mixture comprising a protein powder and a polysaccharide powder, and formulating the resulting mixture into a solid oral dosage form, and immersing said solid oral dosage form in gastric fluid. , the polysaccharide powder has powder flow properties that allow interaction with the protein powder such that a protein/polysaccharide complex coacervate is formed in situ, thereby imparting gastroprotective and/or gastroprotective properties to the active ingredient. or a method of preparing a solid oral dosage form that is provided with modified release, the method comprising:
A method wherein the polysaccharide powder has or is adjusted to have one or more of the following powder flow properties:
(a) about 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 49, An angle of repose (α) greater than 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, or 65 degrees;
(b) about 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, a dynamic aggregation index greater than 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50;
(c) about 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, or compression degree (Carr index) greater than 38%;
(d) about 1.18, 1.19, 1.2, 1.21, 1.22, 1.23, 1.24, 1.25, 1.26, 1.27, 1.28, 1. 29, 1.3, 1.31, 1.32, 1.33, 1.34, 1.35, 1.36, 1.37, 1.38, 1.39, 1.4, 1.41, 1.42, 1.43, 1.44, 1.45, 1.46, 1.47, 1.48, 1.49, 1.5, 1.51, 1.52, 1.53, 1. Hausner ratio greater than 54, 1.55, 1.56, 1.57, 1.58, 1.59 or 1.6; or
(e) Any combination of (a) to (d). 前記固体経口剤形が、請求項１～１４のいずれか一項に定義される経口送達系である、請求項１５に記載の方法。 16. The method of claim 15 , wherein the solid oral dosage form is an oral delivery system as defined in any one of claims 1-14 . 治療に使用するための、請求項１～１４のいずれか一項に記載の経口送達系、または請求項１５または１６に記載の方法によって生成された経口剤形。 An oral dosage form produced by an oral delivery system according to any one of claims 1 to 14 or a method according to claims 15 or 16 for use in therapy. 胃保護および／または放出調節から利益を得る前記有効成分の対象への投与によって改善される疾患または状態を治療するための、請求項１～１４のいずれか一項に記載の経口送達系、または請求項１５または１６に記載の方法で生成された経口剤形。 Oral delivery system according to any one of claims 1 to 14 for treating a disease or condition ameliorated by administration of said active ingredient to a subject that benefits from gastroprotection and/or modified release , or An oral dosage form produced by the method of claim 15 or 16 .
JP2022537400A 2019-12-17 2020-12-16 Oral delivery system based on in situ formation of protein/polysaccharide coacervates Pending JP2023506539A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962949130P 2019-12-17 2019-12-17
US62/949,130 2019-12-17
PCT/CA2020/051726 WO2021119810A1 (en) 2019-12-17 2020-12-16 Oral delivery systems based on in situ forming protein/polysaccharide coacervates

Publications (2)

Publication Number Publication Date
JP2023506539A JP2023506539A (en) 2023-02-16
JPWO2021119810A5 true JPWO2021119810A5 (en) 2023-12-25

Family

ID=76476907

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022537400A Pending JP2023506539A (en) 2019-12-17 2020-12-16 Oral delivery system based on in situ formation of protein/polysaccharide coacervates

Country Status (12)

Country Link
US (2) US11737987B2 (en)
EP (1) EP3937983A4 (en)
JP (1) JP2023506539A (en)
KR (1) KR20220114618A (en)
CN (1) CN114867496A (en)
AU (1) AU2020406676A1 (en)
BR (1) BR112022011714A2 (en)
CA (1) CA3161198A1 (en)
IL (1) IL293904A (en)
MX (1) MX2022007326A (en)
WO (1) WO2021119810A1 (en)
ZA (1) ZA202206754B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115886255A (en) * 2022-10-31 2023-04-04 中国农业大学 High-stability blueberry anthocyanin binary gel tablet and preparation method thereof

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3069327A (en) 1960-09-19 1962-12-18 Arthur C Eldridge Soybean whey protein-polysaccharide complex
US3312594A (en) * 1963-06-21 1967-04-04 Squibb & Sons Inc Longlasting troche
US3558768A (en) 1969-12-19 1971-01-26 Sterling Drug Inc Sustained release pharmaceutical compositions
SE7607758L (en) 1975-07-28 1977-01-29 Mueller Hans Dr Ing Fa KIT FOR MANUFACTURE OF EGG WHITE FROM WHEAT FLOUR
US4451446A (en) 1982-03-04 1984-05-29 Smithkline-Rit Process for the preparation of polysaccharide-protein complexes from bacterial capsules, obtained products and immunogenic compositions containing them
EP0109688A3 (en) 1982-11-23 1986-12-03 The Wellcome Foundation Limited Improved complexes, processes for obtaining them and formulations containing such complexes
GB2148901A (en) 1983-10-04 1985-06-05 Johnson & Johnson Protein/polysaccharide complexes
ES2172793T3 (en) 1996-06-17 2002-10-01 Janssen Pharmaceutica Nv BICONVEX DOSAGE FORMS OF QUICK DISINTEGRATION.
US6632451B2 (en) 1999-06-04 2003-10-14 Dexcel Pharma Technologies Ltd. Delayed total release two pulse gastrointestinal drug delivery system
CA2435681C (en) 2001-01-23 2011-06-21 Aventis Pasteur Multivalent meningococcal polysaccharide-protein conjugate vaccine
WO2003026687A1 (en) 2001-09-28 2003-04-03 Nutraceutix, Inc. Delivery system for biological component
EP1371410A1 (en) 2002-06-14 2003-12-17 NIZO food research Complex coacervates containing whey proteins
KR101175774B1 (en) 2002-11-04 2012-08-21 오션 뉴트리션 캐나다 리미티드 Microcapsules having multiple shells and method for the preparation thereof
US8137728B2 (en) 2004-03-11 2012-03-20 University Of Massachusetts Biopolymer encapsulation and stabilization of lipid systems and methods for utilization thereof
KR100858848B1 (en) 2006-05-23 2008-09-17 한올제약주식회사 Pharmaceutical compositions and formulations of Metformin extended release tablets
US20080254119A1 (en) * 2007-04-16 2008-10-16 Wyeth Imbedded liquid lubricants for tableting
KR100813224B1 (en) 2007-08-24 2008-03-13 한양대학교 산학협력단 Thermo-reversible coacervate combination gels for protein delivery
IL188647A0 (en) 2008-01-08 2008-11-03 Orina Gribova Adaptable structured drug and supplements administration system (for oral and/or transdermal applications)
CA2726700C (en) 2008-06-12 2018-05-22 Universite Laval Modified protein excipient for delayed-release tablet
DK2196097T3 (en) 2008-12-04 2014-07-07 Nestec Sa Hydrolyzed protein-polysaccharide complexes
US9167847B2 (en) 2009-03-16 2015-10-27 Philip Morris Usa Inc. Production of coated tobacco particles suitable for usage in a smokeless tobacoo product
GB201005976D0 (en) 2010-04-09 2010-05-26 Univ Aston A freeze-dried tablet
WO2014145057A1 (en) 2013-03-15 2014-09-18 GreenStract, LLC Plant-based compositions and uses thereof
US20150050245A1 (en) 2013-08-14 2015-02-19 Tntgamble, Inc. Methods and delivery system for beneficial additive and subtractive biological agents to promote balanced mammalian gastrointestinal flora
US10166185B2 (en) * 2015-06-09 2019-01-01 J. Rettenmaier & Söhne Gmbh + Co Kg Excipient and oral solid dosage forms for oily drugs
WO2017022490A1 (en) 2015-07-31 2017-02-09 不二製油グループ本社株式会社 Method for producing polysaccharide-protein complex
US20190076535A1 (en) 2017-02-20 2019-03-14 Joshua Alan Held Crosslinked protein-polysaccharide complexed consumable macrocapsule
AU2018279977B2 (en) * 2017-06-06 2024-02-22 Biogrund Gmbh Natural and organic binder compositions for oral solid dosage forms
US11425924B2 (en) 2018-01-15 2022-08-30 Glanbia Nutritionals, Ltd. Composition and method for controlled-release of amino acids

Similar Documents

Publication Publication Date Title
JP2022136170A (en) Methods of manufacture of nut flour and formulations for oral immunotherapy
US6793942B2 (en) Composition and method for treating the effects of diseases and maladies
US6841544B2 (en) Composition and method for treating the effects of diseases and maladies
AU2009266076B2 (en) Antiallergic marine biopolymers
US20020128273A1 (en) Composition and method for treating the effects of diseases and maladies
TW200845972A (en) Pharmaceutical composition
US20010044410A1 (en) Composition and method for treating the effects of diseases and maladies
EP3131568B1 (en) Compositions based on xyloglucan and proteins for the treatment of intestinal disorders
TWI710379B (en) Tablet
JP2020518596A (en) Chinese herbal medicine extract effective for depression, its preparation method and use
JP2023016043A (en) Gamma-polyglutamic acid and zinc compositions
JP2013063940A (en) Agent for preventing or improving osteoporosis
TW201501731A (en) Enteric coated tablet
US20020034555A1 (en) Composition and method for treating the effects of diseases and maladies
JPWO2021119810A5 (en)
KR101727132B1 (en) Composition for preventing or treating of Henoch-Schonlein Purpura
WO2017146053A1 (en) Pharmaceutical composition particles and orally disintegrating preparation including same
JP2014221847A (en) Sugar-coated preparation and method for producing the same
JPS6365653B2 (en)
JPWO2005032569A1 (en) Pharmaceutical composition
JP5977672B2 (en) Suspension for oral administration of ibuprofen ricinate
JP4610730B2 (en) Composition for calcium supplementation
US20010043959A1 (en) Composition and method for treating the effects of diseases and maladies
JP7177696B2 (en) Activity reduction inhibitor of bioactive peptide or bioactive protein
KR20150126383A (en) Composition for oral administration for binding aldehydes in the gastrointestinal tract